- Home
- ARL vs AARD Comparison
ARL vs AARD Comparison
Compare ARL & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARL
- AARD
- Stock Information
- Founded
- ARL 1999
- AARD 2017
- Country
- ARL United States
- AARD United States
- Employees
- ARL N/A
- AARD N/A
- Industry
- ARL Building operators
- AARD Biotechnology: Pharmaceutical Preparations
- Sector
- ARL Real Estate
- AARD Health Care
- Exchange
- ARL Nasdaq
- AARD Nasdaq
- Market Cap
- ARL 198.8M
- AARD 216.6M
- IPO Year
- ARL N/A
- AARD 2025
- Fundamental
- Price
- ARL $11.55
- AARD $8.29
- Analyst Decision
- ARL
- AARD Strong Buy
- Analyst Count
- ARL 0
- AARD 4
- Target Price
- ARL N/A
- AARD $31.50
- AVG Volume (30 Days)
- ARL 10.5K
- AARD 132.2K
- Earning Date
- ARL 05-08-2025
- AARD 01-01-0001
- Dividend Yield
- ARL N/A
- AARD N/A
- EPS Growth
- ARL N/A
- AARD N/A
- EPS
- ARL N/A
- AARD N/A
- Revenue
- ARL $48,767,000.00
- AARD N/A
- Revenue This Year
- ARL N/A
- AARD N/A
- Revenue Next Year
- ARL N/A
- AARD N/A
- P/E Ratio
- ARL N/A
- AARD N/A
- Revenue Growth
- ARL N/A
- AARD N/A
- 52 Week Low
- ARL $10.25
- AARD $6.79
- 52 Week High
- ARL $22.77
- AARD $19.58
- Technical
- Relative Strength Index (RSI)
- ARL 40.46
- AARD N/A
- Support Level
- ARL $10.75
- AARD N/A
- Resistance Level
- ARL $11.49
- AARD N/A
- Average True Range (ATR)
- ARL 0.81
- AARD 0.00
- MACD
- ARL -0.23
- AARD 0.00
- Stochastic Oscillator
- ARL 31.10
- AARD 0.00
About ARL American Realty Investors Inc.
American Realty Investors Inc is a real estate company. The company acquires, develops, and owns income-producing residential and commercial real estate properties. Its segment involves the Residential segment and the Commercial segment. The residential segment is engaged in the acquisition, development, ownership, and management of multifamily properties and the Commercial segment is engaged in the acquisition, ownership, and management of commercial real estate properties. Its holdings include apartments, office buildings, retail centers, and parcels of land.
About AARD Aardvark Therapeutics Inc. Common Stock
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.